Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Earnings for Ultragenyx Pharmaceutical Inc. (RARE)
Earnings in 2023 (TTM): $-608,464,000
According to Ultragenyx Pharmaceutical Inc.'s latest financial reports the company's current earnings (TTM) are $-608,464,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ultragenyx Pharmaceutical Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-608,464,000 | $-606,639,000 |
| 2022 | $-701,725,000 | $-707,421,000 |
| 2021 | $-452,981,000 | $-454,025,000 |
| 2020 | $-185,359,000 | $-186,566,000 |
| 2019 | $-399,444,000 | $-402,727,000 |
| 2018 | $-197,097,000 | $-197,611,000 |
| 2017 | $-318,338,000 | $-302,139,000 |
| 2016 | $-245,839,000 | $-245,874,000 |
| 2015 | $-145,618,000 | $-145,618,000 |
| 2014 | $-59,802,000 | $-59,802,000 |
| 2013 | $-35,070,000 | $-35,070,000 |
| 2012 | $-16,334,000 | $-16,334,000 |
| 2011 | $-6,849,000 | $-6,849,000 |